Qiongzi Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Qiongzi Wang has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Xueshan Qiu
Department of Pathology, College of Basic Medical Sciences, China Medical University, Shenyang, China
4 shared publications - Hongbo Su
Department of Pathology, The First Hospital of China Medical University, Shenyang, China
2 shared publications - Hongjiu Ren
Department of Pathology, College of Basic Medical Sciences and The First Affiliated Hospital, China Medical University, Shenyang 110001, People's Republic of China
2 shared publications Huiying Lv
Henan International Joint Laboratory of Immunology and Model Animals, School of Medical Technology, Xinxiang Medical University, Xinxiang, China
2 shared publications- Jun Jiang
Department of Urology The Second Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou People's Republic of China
2 shared publications - Yitong Xu
Department of Pathology, College of Basic Medical Sciences and The First Affiliated Hospital, China Medical University, Shenyang 110001, People's Republic of China
2 shared publications
Latest Publications
- Open Access
- 14 March 2026
- Published by Springer Nature in Cell Death Discovery
- Vol. 12 (1)
SOX4 induces cisplatin resistance in cervical cancer cells by inhibiting aerobic glycolysis
Cisplatin resistance remains a major cause of chemotherapy failure in cervical cancer. Although our previous work identified that SOX4 promotes cisplatin resistance in cervical cancer cells, the underlying mechanism has not been fully elucidated. Here, we demonstrated that SOX4 not only induces resistance to cisplatin but also to oxaliplatin and carboplatin, suggesting its potential role as a multidrug resistance gene. Overexpression of SOX4 markedly suppressed glycolytic activity in cervical cancer cells and induced cisplatin resistance by inhibiting both the intrinsic and extrinsic apoptotic pathways. Rescue and neutralization experiments further indicated that SOX4 upregulates SIRT1, which subsequently represses the expression of GLUT1 on the cell membrane. This suppression leads to diminished cellular glucose uptake, resulting in decreased glycolysis and overall metabolic activity. Given that cisplatin preferentially targets highly proliferating cells, SOX4-driven metabolic deceleration enables cervical cancer cells to evade cisplatin-mediated cytotoxicity. Together, these findings demonstrate that SOX4 enhances cisplatin resistance in cervical cancer through SIRT1-upregulated suppression of glycolysis.
- 14 March 2026
- Published by Springer Nature in Cell Death Discovery
- Vol. 12 (1)
Open AccessSOX4 induces cisplatin resistance in cervical cancer cells by inhibiting aerobic glycolysis
Cisplatin resistance remains a major cause of chemotherapy failure in cervical cancer. Although our previous work identified that SOX4 promotes cisplatin resistance in cervical cancer cells, the underlying mechanism has not been fully elucidated. Here, we demonstrated that SOX4 not only induces resistance to cisplatin but also to oxaliplatin and carboplatin, suggesting its potential role as a multidrug resistance gene. Overexpression of SOX4 markedly suppressed glycolytic activity in cervical cancer cells and induced cisplatin resistance by inhibiting both the intrinsic and extrinsic apoptotic pathways. Rescue and neutralization experiments further indicated that SOX4 upregulates SIRT1, which subsequently represses the expression of GLUT1 on the cell membrane. This suppression leads to diminished cellular glucose uptake, resulting in decreased glycolysis and overall metabolic activity. Given that cisplatin preferentially targets highly proliferating cells, SOX4-driven metabolic deceleration enables cervical cancer cells to evade cisplatin-mediated cytotoxicity. Together, these findings demonstrate that SOX4 enhances cisplatin resistance in cervical cancer through SIRT1-upregulated suppression of glycolysis.
- 15 May 2025
- Published by Elsevier in Food Chemistry
- Vol. 487, 144748
Green synthesis of paulownia flower-derived carbon dots for sensitive fluorescent detection of paclobutrazol
- 15 May 2025
- Published by Elsevier in Food Chemistry
- Vol. 487, 144748
Green synthesis of paulownia flower-derived carbon dots for sensitive fluorescent detection of paclobutrazol
- Open Access
- 8 February 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1-13
Isoacteoside alleviates hepatocellular carcinoma progression by inhibiting PDHB-mediated reprogramming of glucose metabolism
Pyruvate dehydrogenase B (PDHB) is an important component of the pyruvate dehydrogenase complex and is implicated in altering tumor metabolism and promoting malignancy. However, the specific impact of PDHB on hepatocellular carcinoma (HCC) metabolic reprogramming and its role in tumor progression remain to be elucidated. In our investigation, we have discerned a pronounced elevation in PDHB expression within HCC, intricately linked to delayed tumor staging, heightened tumor grading, and diminished prognostic outcomes. PDHB overexpression drives tumor growth and metastasis in vitro and in vivo. Mechanistically, PDHB mediates metabolic reprogramming by binding to the promoter regions of SLC2A1, GPI, and PKM2, promoting glycolysis-related gene transcription, contributes to HCC sorafenib resistance. In addition, Isoacteoside is a targeted inhibitor of PDHB and exert antitumor effects on HCC. In the mouse xenograft model, the combination of isoacteoside and sorafenib shows significantly better effects than sorafenib alone. In summary, our study validates PDHB as an oncogenic drug resistance-related gene capable of predicting HCC tumor progression. PDHB and Isoacteoside could be potential avenues for targeted and combination therapies in liver cancer.
- 8 February 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1-13
Open AccessIsoacteoside alleviates hepatocellular carcinoma progression by inhibiting PDHB-mediated reprogramming of glucose metabolism
Pyruvate dehydrogenase B (PDHB) is an important component of the pyruvate dehydrogenase complex and is implicated in altering tumor metabolism and promoting malignancy. However, the specific impact of PDHB on hepatocellular carcinoma (HCC) metabolic reprogramming and its role in tumor progression remain to be elucidated. In our investigation, we have discerned a pronounced elevation in PDHB expression within HCC, intricately linked to delayed tumor staging, heightened tumor grading, and diminished prognostic outcomes. PDHB overexpression drives tumor growth and metastasis in vitro and in vivo. Mechanistically, PDHB mediates metabolic reprogramming by binding to the promoter regions of SLC2A1, GPI, and PKM2, promoting glycolysis-related gene transcription, contributes to HCC sorafenib resistance. In addition, Isoacteoside is a targeted inhibitor of PDHB and exert antitumor effects on HCC. In the mouse xenograft model, the combination of isoacteoside and sorafenib shows significantly better effects than sorafenib alone. In summary, our study validates PDHB as an oncogenic drug resistance-related gene capable of predicting HCC tumor progression. PDHB and Isoacteoside could be potential avenues for targeted and combination therapies in liver cancer.
- Open Access
- 6 October 2020
- Published by Springer Nature in Research Square
Comprehensive Analysis of the Expression and Prognosis for IRXs in Non-small Cell Lung Cancer
Iroquoishomeobox transcription factor family (IRXs)have been increasingly reported to play roles in suppressing or promoting a variety of cancers, however, little is known about their expression and prognostic value in terms of human lung cancer. In this study, Oncomine, GEPIA, Kaplan-Meier plotter, and cBioPortal databases were used to analyze the different expression patterns and prognostic values of six IRXs in NSCLC and examine their related functions and pathways using GO enrichment. Compared with normal lung cancer tissues, the expression of IRX1 and IRX2 in NSCLC tissues was significantly lower and was positively correlated with the 10-year survival rate of patients. Higher expression of IRX4 was related to terminal tumors, and suggested a poor prognosis. It was also found that IRXs may play a tumor-suppressive role in the localization of cytoplasm in NSCLC, while localization in the nucleus suggests a more malignant behavior. Together these results suggest that IRX1 and IRX2 may be prognostic indicators of LUAD, and that IRX4 could be a potential target for LUAD treatment.
- 6 October 2020
- Published by Springer Nature in Research Square
Open AccessComprehensive Analysis of the Expression and Prognosis for IRXs in Non-small Cell Lung Cancer
Iroquoishomeobox transcription factor family (IRXs)have been increasingly reported to play roles in suppressing or promoting a variety of cancers, however, little is known about their expression and prognostic value in terms of human lung cancer. In this study, Oncomine, GEPIA, Kaplan-Meier plotter, and cBioPortal databases were used to analyze the different expression patterns and prognostic values of six IRXs in NSCLC and examine their related functions and pathways using GO enrichment. Compared with normal lung cancer tissues, the expression of IRX1 and IRX2 in NSCLC tissues was significantly lower and was positively correlated with the 10-year survival rate of patients. Higher expression of IRX4 was related to terminal tumors, and suggested a poor prognosis. It was also found that IRXs may play a tumor-suppressive role in the localization of cytoplasm in NSCLC, while localization in the nucleus suggests a more malignant behavior. Together these results suggest that IRX1 and IRX2 may be prognostic indicators of LUAD, and that IRX4 could be a potential target for LUAD treatment.
- Open Access
- 12 February 2019
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 38 (1) , 1-13
DRAM2 acts as an oncogene in non-small cell lung cancer and suppresses the expression of p53
Damage-regulated autophagy modulator 2(DRAM2) is associated with autophagy processes. However, the role of DRAM2 in the progression of human neoplasms is still unknown. Here, we show that DRAM2 may act as an oncogenic regulator in non-small cell lung cancer (NSCLC). Tumor specimens from 259 NSCLC patients were collected and analyzed. Transwell migration, cell cycle analysis, MTT and colony formation assays were performed to determine the effect of DRAM2 overexpression and knockdown on NSCLC-cell migration and proliferation. Western blotting confirmed the expression of DRAM2, p53, and the other involved proteins. DRAM2 was preferentially upregulated in NSCLC tissues and higher expression of DRAM2 in NSCLC correlated with tumor node metastases stage and lymph node metastasis. Additionally, DRAM2 overexpression promoted cell metastasis and proliferation in vitro, while knockdown of DRAM2 expression yielded opposite result. Furthermore, DRAM2 overexpression increased the expression of proteins RAC1, RHOA, RHOC, ROCK1, and decreased RHOB expression, all of which are cell migration factors. DRAM2 overexpression also increased proteins CDK4, CyclinD3, and decreased p27 expression, all of which are cell cycle-related factors. Consistently knocked down DRAM2 had the opposite effect. We also found that DRAM2 expression was negatively correlated to p53 expression. Knockdown of DRAM2 caused an increase of p53 and p21 expression, and overexpression of p53 caused a decrease of DRAM2 expression. Finally, absence of p53 did not influence the function of DRAM2 in NSCLC, but overexpression of p53 repressed its function. DRAM2 plays an oncogenic role in NSCLC via regulating p53 expression. Therefore, DRAM2 may act as an oncogene in NSCLC and could serve as a prognostic factor and potential target for NSCLC treatment.
- 12 February 2019
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 38 (1) , 1-13
Open AccessDRAM2 acts as an oncogene in non-small cell lung cancer and suppresses the expression of p53
Damage-regulated autophagy modulator 2(DRAM2) is associated with autophagy processes. However, the role of DRAM2 in the progression of human neoplasms is still unknown. Here, we show that DRAM2 may act as an oncogenic regulator in non-small cell lung cancer (NSCLC). Tumor specimens from 259 NSCLC patients were collected and analyzed. Transwell migration, cell cycle analysis, MTT and colony formation assays were performed to determine the effect of DRAM2 overexpression and knockdown on NSCLC-cell migration and proliferation. Western blotting confirmed the expression of DRAM2, p53, and the other involved proteins. DRAM2 was preferentially upregulated in NSCLC tissues and higher expression of DRAM2 in NSCLC correlated with tumor node metastases stage and lymph node metastasis. Additionally, DRAM2 overexpression promoted cell metastasis and proliferation in vitro, while knockdown of DRAM2 expression yielded opposite result. Furthermore, DRAM2 overexpression increased the expression of proteins RAC1, RHOA, RHOC, ROCK1, and decreased RHOB expression, all of which are cell migration factors. DRAM2 overexpression also increased proteins CDK4, CyclinD3, and decreased p27 expression, all of which are cell cycle-related factors. Consistently knocked down DRAM2 had the opposite effect. We also found that DRAM2 expression was negatively correlated to p53 expression. Knockdown of DRAM2 caused an increase of p53 and p21 expression, and overexpression of p53 caused a decrease of DRAM2 expression. Finally, absence of p53 did not influence the function of DRAM2 in NSCLC, but overexpression of p53 repressed its function. DRAM2 plays an oncogenic role in NSCLC via regulating p53 expression. Therefore, DRAM2 may act as an oncogene in NSCLC and could serve as a prognostic factor and potential target for NSCLC treatment.
- Open Access
- 13 August 2018
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 37 (1) , 1-13
MKRN2 inhibits migration and invasion of non-small-cell lung cancer by negatively regulating the PI3K/Akt pathway
Makorin RING zinc finger-2 (MKRN2) belongs to the makorin RING zinc finger family and is a novel ubiquitin E3 ligase targeting the p65 subunit of NF-κB to negatively regulate inflammatory responses; however, the relationship between MKRN2 and tumorigenesis remains unclear. In this study, we clarified the role of MKRN2 in non-small cell lung cancer (NSCLC). Tumor specimens collected from 261 NSCLC patients from 2013 to 2017 were retrieved from the Pathology Archive of the First Affiliated Hospital of China Medical University, and we performed assays to evaluate MKRN2 expression and to determine the impact of MKRN2 silencing and overexpression on NSCLC-cell migration and invasion. We demonstrated that MKRN2 expression was associated with lymph node metastasis, p-TNM stage, cancer-cell differentiation, and poor prognosis. By altering the expression of MKRN2 in selected cell lines, we found that MKRN2 inhibited cell migration and invasion through downregulation of the PI3K/Akt pathway. These results suggested that MKRN2 inhibited NSCLC progression by reducing the metastatic potential of cancer cells. Our findings provide critical insight into the association of MKRN2 expression with favorable clinicopathological characteristics in NSCLC patients and suggested that MKRN2 plays a role in inhibiting NSCLC development.
- 13 August 2018
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 37 (1) , 1-13
Open AccessMKRN2 inhibits migration and invasion of non-small-cell lung cancer by negatively regulating the PI3K/Akt pathway
Makorin RING zinc finger-2 (MKRN2) belongs to the makorin RING zinc finger family and is a novel ubiquitin E3 ligase targeting the p65 subunit of NF-κB to negatively regulate inflammatory responses; however, the relationship between MKRN2 and tumorigenesis remains unclear. In this study, we clarified the role of MKRN2 in non-small cell lung cancer (NSCLC). Tumor specimens collected from 261 NSCLC patients from 2013 to 2017 were retrieved from the Pathology Archive of the First Affiliated Hospital of China Medical University, and we performed assays to evaluate MKRN2 expression and to determine the impact of MKRN2 silencing and overexpression on NSCLC-cell migration and invasion. We demonstrated that MKRN2 expression was associated with lymph node metastasis, p-TNM stage, cancer-cell differentiation, and poor prognosis. By altering the expression of MKRN2 in selected cell lines, we found that MKRN2 inhibited cell migration and invasion through downregulation of the PI3K/Akt pathway. These results suggested that MKRN2 inhibited NSCLC progression by reducing the metastatic potential of cancer cells. Our findings provide critical insight into the association of MKRN2 expression with favorable clinicopathological characteristics in NSCLC patients and suggested that MKRN2 plays a role in inhibiting NSCLC development.
- Open Access
- 7 July 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (13) , 10880-10890
E3 ubiquitin ligase tripartite motif-containing 71 promotes the proliferation of non-small cell lung cancer through the inhibitor of kappaB-α/nuclear factor kappaB pathway
E3 ubiquitin ligase tripartite motif-containing 71 promotes the proliferation of non-small cell lung cancer through the inhibitor of kappaB-α/nuclear factor kappaB pathway E3 ubiquitin ligase tripartite motif-containing 71 promotes the proliferation of non-small cell lung cancer through the inhibitor of kappaB-α/nuclear factor kappaB pathway
- 7 July 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (13) , 10880-10890
Open AccessE3 ubiquitin ligase tripartite motif-containing 71 promotes the proliferation of non-small cell lung cancer through the inhibitor of kappaB-α/nuclear factor kappaB pathway
E3 ubiquitin ligase tripartite motif-containing 71 promotes the proliferation of non-small cell lung cancer through the inhibitor of kappaB-α/nuclear factor kappaB pathway E3 ubiquitin ligase tripartite motif-containing 71 promotes the proliferation of non-small cell lung cancer through the inhibitor of kappaB-α/nuclear factor kappaB pathway